Patents by Inventor Ninghan Feng

Ninghan Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911353
    Abstract: The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: February 27, 2024
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Yongquan Chen, Hongyan Qu, Chunlei Tang, Guosheng Wu, Guozhen Cui, Ninghan Feng, Xiaoying Wang, Kai Shan, Shenglong Zhu, Lengyun Wei
  • Patent number: 11704808
    Abstract: A segmentation method for tumor regions in a pathological image of clear cell renal cell carcinoma based on deep learning includes data acquisition and pre-processing, building and training of a classification network SENet and prediction of tumor regions. The present invention studies clear cell renal cell carcinoma based on pathological images, yielding results with higher reliability than judgments made based on CT or MRI images. The present invention overcomes the drawback that the previous research on clear cell renal cell carcinoma is only limited to judgment on presence by being able to visually provide the position and size of tumor regions, which is convenient for the medical profession to better study the pathogenesis and directions to the treatment of clear cell renal cell carcinoma.
    Type: Grant
    Filed: February 23, 2023
    Date of Patent: July 18, 2023
    Assignee: WUXI SECOND PEOPLE'S HOSPITAL
    Inventors: Ninghan Feng, Hong Tang, Guanzhen Yu, Jinzhu Su, Yang Wang, Yangkun Feng, Peng Jiang
  • Publication number: 20210046027
    Abstract: The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Inventors: Yongquan CHEN, Hongyan QU, Chunlei TANG, Guosheng WU, Guozhen CUI, Ninghan Feng, Xiaoying Wang, Kai SHAN, Shenglong ZHU, Lengyun WEI